STERIS LIMITED

1. Risk Rating: LOW

The risk rating for STERIS LIMITED is LOW. This assessment is primarily driven by the company's position as a wholly-owned intermediate holding company within the larger STERIS plc group (a publicly traded entity on the NYSE). While the standalone financials reveal negligible cash reserves, the explicit mention of group cash pooling arrangements and a revolving credit facility provides strong implicit and explicit parental support, effectively neutralizing immediate solvency and liquidity threats at the standalone level.

2. Key Concerns

• Minimal Standalone Liquidity: The standalone balance sheet shows cash of merely £51 (or $51,000 if the underlying text implies thousands), which is drastically insufficient to cover operational or administrative expenses independently. The company is entirely reliant on the group cash pooling structure to meet day-to-day obligations.
• Total Operational Dependence: As an intermediate holding company with no employees and US-based directors who are executive officers of the parent, the entity has no independent operational capacity. Its financial viability is completely tethered to the financial health and strategic decisions of STERIS plc.
• Foreign Currency Exposure: The company’s functional currency is USD, but it holds debt in Euros and GBP. While managed at the group level, unhedged exposure on these intercompany or external balances could introduce volatility to the standalone financial statements given macroeconomic currency fluctuations.

3. Positive Indicators

• Strong Parental Backing: The company is 100% owned by STERIS plc, a substantial multinational organization. The strategic report explicitly states the company utilizes group cash pooling and a group Revolving Credit Facility, indicating integrated financial support.
• Robust Profitability and Net Asset Position: The year ending March 2025 shows a significant increase in profit after tax ($73.84M vs $13.26M in 2024) and maintains solid net assets ($329.36M). This demonstrates strong performance in its role as a dividend-receiving holding entity.
• Regulatory and Filing Compliance: The company files full accounts audited by a Big 4 firm (Ernst & Young LLP). There are no overdue filings, and the confirmation statement is up to date, reflecting strong governance and administrative compliance.

4. Due Diligence Notes

• Intercompany Balances: The bulk of the company's current assets and liabilities likely consists of intercompany loans and receivables. An investigator should review the recoverability of these balances and the terms of the cash pooling arrangement to ensure there are no subordination risks that could impair the company in a distant group insolvency scenario.
• Group-Level Financial Health: Because STERIS LIMITED is effectively a pass-through entity, any true assessment of risk requires a deep dive into the consolidated financial statements of STERIS plc. The going concern note explicitly relies on the group's consolidated cash flows.
• Dividend Upstreaming: The company paid out $78.9M in ordinary dividends in 2025, and subsequently paid $117.8M post-year-end. It is important to monitor whether these upstream payments are leaving the entity overly reliant on future subsidiary dividends to service its own external debt obligations.